Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Sandhoff Disease (Jatzkewitz-Pilz Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions.
Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. It is caused by a deficiency of the enzyme beta-hexosaminidase. Symptoms include progressive nervous system deterioration, problems initiating and controlling muscles and movement, increased startle reaction to sound, early blindness, seizures, spasticity, and myoclonus. Treatment includes anticonvulsants to control seizures.
The Sandhoff Disease (Jatzkewitz-Pilz Syndrome) drugs in development market research report provide comprehensive information on the therapeutics under development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sandhoff Disease (Jatzkewitz-Pilz Syndrome) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Sandhoff Disease (Jatzkewitz-Pilz Syndrome) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 10 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Sandhoff Disease (Jatzkewitz-Pilz Syndrome) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Sandhoff Disease (Jatzkewitz-Pilz Syndrome) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sandhoff Disease (Jatzkewitz-Pilz Syndrome) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AceLink Therapeutics IncAzafaros BV
Duke University
IntraBio Ltd
JCR Pharmaceuticals Co Ltd
McMaster University
Orphi Therapeutics Inc
Polaryx Therapeutics Inc
Sanofi
Taysha Gene Therapies Inc
University of Massachusetts
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Sandhoff Disease (Jatzkewitz-Pilz Syndrome) reports